Efficacy of α-lipoic acid in diabetic neuropathy (Q38266297)

1 September 2017

1 reference

title

Efficacy of α-lipoic acid in diabetic neuropathy (English)

1 reference

1 September 2017

Nikolaos Papanas

1

1 reference

PubMed ID

25381809

1 September 2017

Dan Ziegler

series ordinal

2

1 reference

PubMed ID

25381809

1 September 2017

language of work or name

English

0 references

publication date

10 November 2014

1 reference

Expert Opinion on Pharmacotherapy

1 September 2017

1 reference

1 September 2017

15

1 reference

1 September 2017

18

1 reference

1 September 2017

2721-2731

1 reference

Prevalence of polyneuropathy in pre-diabetes and diabetes is associated with abdominal obesity and macroangiopathy: the MONICA/KORA Augsburg Surveys S2 and S3.

1 September 2017

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.972935

Diabetic neuropathies: update on definitions, diagnostic criteria, estimation of severity, and treatments

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.972935

The diabetic foot: established and emerging treatments

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.972935

Current options and perspectives in the treatment of diabetic neuropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.972935

Painful diabetic polyneuropathy: epidemiology, pain description, and quality of life

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.972935

Diabetic cardiovascular autonomic neuropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.972935

Neuropathy: the crystal ball for cardiovascular disease?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.972935

A simple new non-invasive sweat indicator test for the diagnosis of diabetic neuropathy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.972935

Whither pathogenetic treatments for diabetic polyneuropathy?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.972935

Thioctic acid for patients with symptomatic diabetic polyneuropathy: a critical review

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.972935

Ranirestat for the management of diabetic sensorimotor polyneuropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.972935

Aldose reductase inhibitors in the treatment of diabetic peripheral neuropathy: a review

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.972935

Ruboxistaurin for the treatment of diabetic peripheral neuropathy: a systematic review of randomized clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.972935

Lipid-lowering therapy and peripheral sensory neuropathy in type 2 diabetes: the Fremantle Diabetes Study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.972935

Effect of fenofibrate on amputation events in people with type 2 diabetes mellitus (FIELD study): a prespecified analysis of a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.972935

Dyslipidemia-induced neuropathy in mice: the role of oxLDL/LOX-1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.972935

Vascular risk factors and diabetic neuropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.972935

Neuropathy in prediabetes: does the clock start ticking early?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.972935

Beneficial effects of alpha-lipoic acid and ascorbic acid on endothelium-dependent, nitric oxide-mediated vasodilation in diabetic patients: relation to parameters of oxidative stress

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.972935

Irbesartan and lipoic acid improve endothelial function and reduce markers of inflammation in the metabolic syndrome: results of the Irbesartan and Lipoic Acid in Endothelial Dysfunction (ISLAND) study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.972935

Insufficient glycemic control increases nuclear factor-kappa B binding activity in peripheral blood mononuclear cells isolated from patients with type 1 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.972935

Improvement of insulin-stimulated glucose-disposal in type 2 diabetes after repeated parenteral administration of thioctic acid.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.972935

Thioctic acid--effects on insulin sensitivity and glucose-metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.972935

Alpha-lipoic acid: a multifunctional antioxidant that improves insulin sensitivity in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.972935

Lipoic acid improves nerve blood flow, reduces oxidative stress, and improves distal nerve conduction in experimental diabetic neuropathy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.972935

Effects of DL-alpha-lipoic acid on peripheral nerve conduction, blood flow, energy metabolism, and oxidative stress in experimental diabetic neuropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.972935

Alpha-lipoic acid provides neuroprotection from ischemia-reperfusion injury of peripheral nerve

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.972935

Effect of antioxidant treatment of streptozotocin-induced diabetic rats on endoneurial blood flow, motor nerve conduction velocity, and vascular reactivity of epineurial arterioles of the sciatic nerve.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.972935

Effect of alpha-lipoic acid on vascular responses and nociception in diabetic rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.972935

Alpha-lipoic acid as a pleiotropic compound with potential therapeutic use in diabetes and other chronic diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.972935

Role of mitochondria biogenesis in the metabolic memory associated with the continued progression of diabetic retinopathy and its regulation by lipoic acid

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.972935

Impaired apparent ion demand in experimental diabetic retinopathy: correction by lipoic Acid

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.972935

Reduced expression of lipoic acid synthase accelerates diabetic nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.972935

Mechanisms of antioxidant and pro-oxidant effects of alpha-lipoic acid in the diabetic and nondiabetic kidney

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.972935

Effects of alpha-lipoic acid on the plasma levels of asymmetric dimethylarginine in diabetic end-stage renal disease patients on hemodialysis: a pilot study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.972935

Effect of alpha-lipoic acid on the progression of endothelial cell damage and albuminuria in patients with diabetes mellitus: an exploratory study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.972935

Effects of combined lipoic acid and pyridoxine on albuminuria, advanced glycation end-products, and blood pressure in diabetic nephropathy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.972935

Corpus cavernosum dysfunction in diabetic rats: effects of combined alpha-lipoic acid and gamma-linolenic acid treatment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.972935

Plasma Kinetics, Metabolism, and Urinary Excretion of Alpha‐Lipoic Acid following Oral Administration in Healthy Volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.972935

Pharmacokinetics of alpha-lipoic acid in subjects with severe kidney damage and end-stage renal disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.972935

Treatment of diabetic polyneuropathy with the antioxidant thioctic acid (alpha-lipoic acid): a two year multicenter randomized double-blind placebo-controlled trial (ALADIN II). Alpha Lipoic Acid in Diabetic Neuropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.972935

Effects of treatment with the antioxidant alpha-lipoic acid on cardiac autonomic neuropathy in NIDDM patients. A 4-month randomized controlled multicenter trial (DEKAN Study). Deutsche Kardiale Autonome Neuropathie

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.972935

Oral treatment with alpha-lipoic acid improves symptomatic diabetic polyneuropathy: the SYDNEY 2 trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.972935

Efficacy and safety of antioxidant treatment with α-lipoic acid over 4 years in diabetic polyneuropathy: the NATHAN 1 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.972935

The sensory symptoms of diabetic polyneuropathy are improved with alpha-lipoic acid: the SYDNEY trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.972935

Postmarketing surveillance of adverse drug reactions: a correlational study approach using multiple data sources

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.972935

Treatment of symptomatic diabetic polyneuropathy with the antioxidant alpha-lipoic acid: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.972935

Alpha lipoic Acid for symptomatic peripheral neuropathy in patients with diabetes: a meta-analysis of randomized controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.972935

A systematic review and meta-analysis of α-lipoic acid in the treatment of diabetic peripheral neuropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.972935

Painful diabetic neuropathy: treatment and future aspects

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.972935

Switching from pathogenetic treatment with alpha-lipoic acid to gabapentin and other analgesics in painful diabetic neuropathy: a real-world study in outpatients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.972935

Systematic review and meta-analysis of pharmacological therapies for painful diabetic peripheral neuropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.972935

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.972935

Painful diabetic neuropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.972935

Drugs for neuropathic pain.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.972935

Metanx in type 2 diabetes with peripheral neuropathy: a randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.972935

Cardiovascular autonomic neuropathy in diabetes: clinical impact, assessment, diagnosis, and management

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.972935

Oxidative Stress in Preretinopathic Diabetes Subjects and Antioxidants

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.972935

10.1517/14656566.2014.972935

21 January 2018

Identifiers

DOI

1 reference

1 September 2017

1 reference

PubMed ID

25381809